SCHEMBL23258869

SCHEMBL23258869

CC(C)(C)OC(=O)Oc1c(Br)ccccc1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 1/20 0.42
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.35
▸ CTSS P25774 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ CA2 P00918 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ BCHE P06276 1/20 0.33
▸ PDK1 Q15118 1/20 0.32
▸ PDK2 Q15119 1/20 0.32
▸ PDK3 Q15120 1/20 0.32
▸ PDK4 Q16654 1/20 0.32
▸ MTNR1A P48039 1/20 0.31
▸ MTNR1B P49286 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18263215 0.86 ELANE (0.47) ELANEKMT2AMEN1NPC1HTT
SCHEMBL23258470 0.79 ELANE (0.39) ELANEKMT2AMEN1NPC1HTT
SCHEMBL21503790 0.78 ELANE (0.46) ELANEKMT2AMEN1NPC1HTT
SCHEMBL23258478 0.78 GABRA1 (0.43) ELANEHSD17B10CTSSCTSKMTNR1A
SCHEMBL23259153 0.77 ELANE (0.42) ELANEKMT2AMEN1NPC1HTT
SCHEMBL23259156 0.77 ELANE (0.40) ELANEKMT2AMEN1NPC1HTT
SCHEMBL17410802 0.74 ELANE (0.40) ELANEKMT2AMEN1NPC1HTT
SCHEMBL23263208 0.74 ELANE (0.37) ELANEKMT2AMEN1CA2PDK2
SCHEMBL23258801 0.74 SCN5A (0.40) ELANECA2TSHR
SCHEMBL23259227 0.73 ELANE (0.36) ELANEKMT2AMEN1KDM4EKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
WO-2021076938-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB ELANE 4033/4885KMT2A 4457/4885MEN1 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback